About Timothy Barberich
Timothy Barberich filed with the SEC as director of TScan Therapeutics from 2021 to 2023.
Form D filings name Timothy Barberich as a director at Gila Therapeutics.
Timothy Barberich reports to the SEC as a director or officer of 10 public companies, including Korro Bio (KRRO), Verastem (VSTM) and Gi Dynamics.
Timothy Barberich first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Timothy Barberich in the role, so the role may have started earlier or lasted longer.
TI
TScan Therapeutics, Inc.
Director
2021 – 2023 · Public company (TCRX)
KI
Korro Bio, Inc.
Director
2019 – 2022 · Public company (KRRO)
VI
Verastem, Inc.
Director
2014 – 2021 · Public company (VSTM)
GI
Gi Dynamics, Inc.
Director
2014 – 2019 · Public company
RI
Rocket Pharmaceuticals, Inc.
Director
2016 – 2017 · Public company (RCKT)
HI
HeartWare International, Inc.
Director
2008 – 2016 · Public company (HTWR)
EI
Eledon Pharmaceuticals, Inc.
Director
2014 – 2016 · Public company (ELDN)
BI
Biosphere Medical Inc.
Director
2006 – 2010 · Public company (BSMD)
SI
Sepracor Inc.
Executive Chairman
2006 – 2009 · Public company (SEPR)
MI
Midatech Pharma US Inc.
Director
2006 · Public company (DARA)
Key Colleagues at Startups
The people Timothy Barberich works with at each company, as listed on that company's latest Form D.
Gila Therapeutics, Inc. · Form D, Dec 6, 2023
CS
Christopher De Souza
Director
PT
Praveen Tyle
Director
JF
Jon Freeman
Executive officer
TV
Thomas Vasicek
Executive officer
RH
Richard Horan
Director
SS
Scott Schorer
Cief Executive Officer and director
SK
Sangeeta Kashyap
Executive officer